Proteasome Treatment may Increase Risk of Cardiovascular Problems

Proteasome Treatment may Increase Risk of Cardiovascular Problems

New study carried out by Abramson Cancer Center of the University of Pennsylvania reports that carfilzomib drug can elevate risk of cardiovascular problems in patients suffering from multiple myeloma.

Findings of the study was published in JAMA Oncology journal in December 28, 2017. The proteasome inhibitor drug carfilzomib is used for treatment of multiple myeloma. Analysis of study shows that 18% of multiple myeloma patients receiving carfilzomib experienced cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks or arrhythmia.

More than eight percent of patients experience severe CVAEs more than twice as common as with other drugs for treating relapsed myeloma. According to estimates of American Cancer Society more than 30,200 people were suffering from MM in 2017. Standard treatments for treatment of these include chemotherapy and radiation and status of the patient can be improved with the use of proteasome inhibitors. FDA approved Carfilzomib as proteasome inhibitors, which has functions in breaking down and eliminate proteins inside a cell.

MM requires more proteasomes for survival of patients. The inhibitor drugs block the cells causing the cells to fill up with protein and die. “Like any cancer therapy, the concern with this approach is that it may have an effect on an otherwise healthy part of the body – in this case, the heart,” said the study’s lead author Adam J. Waxman, MD, a Hematology Oncology fellow in the Perelman School of Medicine at the University of Pennsylvania.

Results of the study found that 18.1% of patients taking carfilzomib experienced CVAE, with 8.2% of those cases being grade three or higher. For comparison, a similar review of bortezomib, another proteasome inhibitor found just 3.8% of patients experienced CVAE and only 2.3 percent were severe.

You may be interested

Hyperloop Technology Market balanced to Reach Insignificant CAGR till 2026
Information Technology and Gadgets
Information Technology and Gadgets

Hyperloop Technology Market balanced to Reach Insignificant CAGR till 2026

Mohit Joshi - August 17, 2018

Hyperloop Technology Market report provides the statistical analysis of “Hyperloop Technology Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the industry space.…

Data Loss Prevention Market Is Expected To Boom Worldwide By 2026
Information Technology and Gadgets
Information Technology and Gadgets

Data Loss Prevention Market Is Expected To Boom Worldwide By 2026

Mohit Joshi - August 17, 2018

Data Loss Prevention Market report provides the statistical analysis of “Data Loss Prevention Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present in the…

Virtual Reality Content Creation Market Poised to Take Off by 2025
Information Technology and Gadgets
Information Technology and Gadgets

Virtual Reality Content Creation Market Poised to Take Off by 2025

Mohit Joshi - August 17, 2018

Virtual Reality Content Creation Market report provides the statistical analysis of “Virtual Reality Content Creation Market: Global Industry Analysis, Size, Share, Growth, Trends, Outlook and Forecasts” present…

Most from this category